We investigated the role of HFE C282Y, H63D, and TMPRSS6 A736V variants in the pathogenesis of iron deficiency anemia (IDA) in celiac disease (CD) patients, at diagnosis and after 1 year of gluten-free diet (GFD). Demographic and clinical features were prospectively recorded for all CD patients between 2013 and 2017. C282Y, H63D, and A736V variants were evaluated for CD patients and controls. Finally, 505 consecutive CD patients and 539 age-matched control subjects were enrolled. At diagnosis, 229 CD subjects had IDA (45.3%), with a subgroup of anemic patients (45.4%) presented persistent IDA at follow-up. C282Y allele frequency was significantly increased in CD compared with controls (1.1% vs 0.2%, P 5 .001), whereas H63D and A736V allele frequencies were similar among patients and controls (P 5 .92 and .84, respectively). At diagnosis, C282Y variant in anemic CD patients was significantly increased compared to nonanemic group (2% and 0.5%, P 5 .04). At follow-up, A736V was significantly increased in IDA persistent than in IDA not persistent (57.7% vs 35.2%, P < .0001). CD patients with H63D mutation showed higher Hb, MCV, serum iron, and ferritin levels than subjects without HFE mutations. Decreased hepcidin values were observed in anemic compared to nonanemic subjects at follow-up (1.22 6 1.14 vs 2.08 6 2.15, P < .001). This study suggests a protective role of HFE in IDA CD patients and confirms the role of TMPRSS6 in predicting oral iron response modulating hepcidin action on iron absorption.
c.187C > G, p.His63Asp, which causes a milder degree of iron overabsorption and is most relevant to disease when paired with the allele for p.Cys282Tyr in compound heterozygotes. 8 In the context of increased intestinal iron absorption, HFE mutations could protect against the development of iron deficiency.
The TMPRSS6 gene encodes for a transmembrane serine protease, matriptase-2, which negatively regulates hepcidin expression by cleaving membrane-bound hemojuvelin. 9, 10 Iron-refractory IDA (IRIDA, OMIM #206200, ORPHA209981) has recently been described as an inherited cause of IDA due to loss-of-function mutations in TMPRSS6 gene. 9 Genome-wide-association studies have identified the TMPRSS6 polymorphism rs855791 as the strongest variable associated with iron status, hemoglobin level, and erythrocyte volume in the general population. 11, 12 Moreover, this polymorphism influences iron overload in hereditary hemochromatosis as well as the development of nonalcoholic fatty liver disease (NAFLD). 13, 14 and it has been associated with IDA in women of reproductive ages. 15 These findings are corroborated by functional studies, which show that rs855791 polymorphism (NM_153609.3:c.2207C > T) causes a nonsynonymous valine to alanine change (p.V736A), and the T allele (encoding valine) reduces the ability of the enzyme to inhibit hepcidin transcription. 16 The aim of this study was to evaluate the pathogenesis of IDA in patients with CD in order to clarify the possible dependence of hemoglobin levels and iron parameters on the rs855791 TMPRSS6, rs1800562 (C282Y) and rs1799945 (H63D) HFE variations at diagnosis and follow-up. Moreover, we investigated the role of TMPRSS6 in iron absorption in treated CD patients in order to personalize their management and follow-up. Because some studies have indicated that TMPRSS6 polymorphisms directly affect hepcidin transcription, we also investigated the association of TMPRSS6 variant with serum hepcidin in CD patients at diagnosis and at follow-up.
| M E TH ODS

| Patients and study design
Between March 2013 and May 2017, we carried out a prospective study including all consecutive adult CD patients (age >18 years and <45) diagnosed and followed up at our Gastrointestinal Unit (Tertiary Centre for Food Intolerance and CD, School of Medicine "Federico II", Naples, Italy). Moreover, we performed a genetic analysis on an agematched population, in which CD diagnosis was excluded, that served as control group.
Demographic, clinical, and laboratory features were recorded for all patients, both at diagnosis and after commencing a gluten-free diet (GDF).
In accordance with current guidelines, CD diagnosis was made in the presence of Marsh 2 histology associated with both anti-tissue transglutaminase (a-tTG) IgA > 7 U/mL and positive anti-endomysial (EMA) antibodies. 1 All subjects with positive serology but negative histology (Marsh 0 or 1) underwent further investigations for genetic susceptibility and were diagnosed as "potential" CD in the presence of HLA DQ2/DQ8. 17 Histopathological findings were graded according to Marsh et al. 18 CD patients were investigated for the presence of anemia at the time of diagnosis and its pathogenesis. CD patients who completed at least one year of GFD were enrolled as it has been shown that recovery from anemia in celiac disease usually requires 6-12 months of such a diet. 4 The treatment of IDA, both oral and parenteral iron, was registered for all patients. Patients who presented persistent IDA despite their clinical responsiveness to GFD were described as an IDApersistent subgroup.
Iron deficiency anemia (IDA) was defined by a hemoglobin (Hb) concentration <13.5 g/dl for men (normal range, 14-18 g/dl) and <12 g/dl for women (normal range, 12-16 g/dl). 19 According to the World Health Organization (WHO) criteria, mild anemia was defined in the presence of Hb 9.5g/dL, moderate anemia when Hb 8.0 g/dL but < 9.5 g/dL, and severe anemia in the presence of Hb < 8.0 g/dL. A hematologic response to GFD was defined as the normalization of the Hb level or by Hb increase 1.0 g/dl. Iron deficiency (ID) was identified on the basis of low-serum iron (normal range, 50-150 mg/dl), and lowserum ferritin (normal range, 20-180 ng/ml). 11,13 CD patients with a thalassemic trait were excluded from this study, as were patients with other known causes of anemia (e.g., inflammatory bowel diseases, neoplasia). Moreover, we excluded from the study all patients aged <18 years, pregnant women or patients with discordant antibodies.
The study was approved by the Federico II University of Naples Ethics Committee (Prot.84/13).
| Samples collection and DNA and hepcidin analysis
All blood samples were collected after overnight fasting, and serum samples for hepcidin dosage were stored at 2708C until analysis.
DNA was extracted from peripheral blood lymphocytes using the Wizard DNA purification kit (Promega, Milan, Italy) according to the manufacturer's instructions. HFE gene mutations (rs1800562 C282Y, rs1799945 H63D) were analyzed by a PCR-restriction method, as previously described. 20, 21 The TMPRSS6 genotype was evaluated by direct sequencing of PCR products and amplified using the primers: Forward
Hepcidin analysis was performed using an updated and validated mass spectrometry (MS)-based assay, which is able to dissect the ironbioactive hepcidin-25 from other hepcidin isoforms. 22 A liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach was used with some modifications. 23 Briefly, Hepcidin-25 synthetic standards and standards for hepcidin-20 and hepcidin-24 isoforms were purchased from Peptide International (Lousiville, USA). Internal standard was added to all samples and the calibration curve. Blank serum (deprived of hepcidin by using charcoal treatment) was used as reference. Samples were treated by solid phase extraction using Oasis hydrophilic-lipophilic balanced reversed-phase (HLB) cartridges or microplates (Waters, Italia). High-performance LC was performed using an X-Terra MS C18 2.5 mm column (Waters, Italia), and detection was obtained using a Triple Quad LC-MS/MS (Agilent Technologies).
Patients with an undetermined value were considered with 0.55 nM. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the relative disease risk conferred by a specific allele. P values <.05 were considered statistically significant.
| Statistical analysis
| RE S U L TS
| Clinical and serological features
Finally, we enrolled a total of 505 consecutive patients diagnosed with celiac disease, comprising 399 females (79%) and 106 males (21%) (P < .001), who were compared with 539 age-matched control subjects.
The hematologic characteristics, iron status, and genetics of patients and controls are reported in Table 1 . The most common symptoms at presentation were diarrhea and weight loss (227 patients, 45%); 263 patients (52%) presented with non-classical CD and 15 patients (3%)
were asymptomatic and were diagnosed during an endoscopic screening of first-degree relatives of patients with CD. Two hundred and twenty-nine patients had iron deficiency anemia (45.3%), with a prevalence that was higher among females (90.4% in females vs 9.6% in males, P 5 .021). There were no differences between anemic and nonanemic patients in terms of age at diagnosis, C-reactive protein levels, and histopathological findings (85.9% Marsh grade 3 in the nonanemic group vs 83% in the anemic group of patients, P 5 .6). Table 2 shows the hematologic characteristics of the 229 anemic patients. One hundred and seventy-nine patients had mild anemia, and only seven had severe anemia.
Most of the anemic patients (76.1%) were treated with oral iron during follow-up, whereas only 7 celiac patients with severe anemia received parenteral iron. Moreover, after one year and despite the clinical responsiveness to GDF and histological normalization, a subgroup of anemic patients (45.4%) presented with persistent IDA.
| TMPRSS6 and HFE mutations in celiac patients and control subjects
The allelic frequencies obtained for HFE gene mutations C282Y, H63D, and TMPRSS6 variant V736A in celiac patients and normal controls are presented in Table 1 . One hundred and thirty-five out of the 505 celiac patients were carriers of one HFE mutations, this frequency not being significantly different from that observed in the control subjects (26.7% vs 24.7%; P 5 .60). The carrier frequency for the C282Y mutation was 2.3% for the patients with CD, which is significantly higher than for the control population (0.4%) (P 5 .005).
For the H63D mutation, the carrier frequency was 24% among the patients with celiac disease, which was not significantly different than that for the controls (24% vs 24%; P 5 .91). The allele frequency of the C282Y mutation was significantly increased in the patients with celiac disease compared with the controls (1.1% vs 0.2%, respectively; P 5 .001). The allele frequency of the H63D mutation was 12% for the patients with CD and 12% for the controls (P 5 .92). The frequency of A736V mutation carriers was similar among celiac patients and controls (73% vs 75%, P 5 .49), as was the allelic frequency (49% vs 50%, P 5 .84).
| TMPRSS6 and HFE mutations in IDA and non-IDA celiac patients
The allelic frequencies of HFE gene mutations and TMPRSS6 variant for IDA and non-IDA CD patients are reported in Table 2 . Allelic frequencies of the H63D HFE mutation among anemic and nonanemic patients were 11.6% and 13.4% (P 5 .24), respectively, whereas C282Y HFE mutation in anemic celiac patients was significantly different from the nonanemic group (2% and 0.5%, P 5 .04).
The allelic frequencies for A736V mutation also differ significantly between anemic (45.4%) and nonanemic CD patients (52.2%) (P 5 .03).
Finally, TMPRSS6 variant rs855791 was present in 88 persistent IDA patients, significantly higher than in non-IDA-persistent patients (84.6% vs 56%, P < .0001) (Supporting Information, Table 1S ). The allele frequency of the A736V mutation was statistically significant in the IDA-persistent patients compared with the IDA-non-persistent ones (57.7% vs 35.2%, respectively; P < .0001) (Supporting Information, Table 1S ). No differences were observed in IDA subgroups for HFE variants (Supporting Information, Table 1S ).
When we evaluated the data of HLA loci in patients with CD, we found no statistically significant differences between CD patients with IDA and those without IDA in terms of frequency of HLA genotypes, as reported in Table 2 . Moreover, we investigated the role of HLA loci in accordance with HFE mutations to evaluate the hypothesis of linkage between HLA and HFE. Interestingly, we found no statistically significant differences between IDA and non- Abbreviations: CD, celiac disease; GFD, gluten-free diet; Hb, haemoglobin; MCV: mean corpuscular volume; n, number; SD, standard deviation.
Nucleotide change is reported in parentheses ().
DE FALCO ET AL. IDA CD subjects after the abovementioned adjustment (Supporting Information, Table 2S ).
| TMPRSS6 and HFE mutations and iron parameters
To investigate the possible role of HFE and TMPRSS6 mutations on iron body status in celiac patients, we analyzed hemoglobin (Hb), mean corpuscular volume (MCV), and ferritin and serum iron levels in patients subdivided according to the presence of the C282Y, H63D, and A736V
variants. Hematologic parameters in the enrolled population according to genotype (homozygotes, heterozygotes, and wild-type) are reported in Table 3A . When the analysis was performed on HFE variants, only the presence of H63D mutation influences iron parameters at diagnosis and after a GFD. In fact, CD patients with the H63D mutation showed higher Hb, MCV, serum iron, and ferritin levels than those observed in subjects without HFE mutations (Table 3A) .
When the same analysis was performed on TMPRSS6 variant, no differences were observed in iron parameters in CD patients with different TMPRSS6 genotypes, either at diagnosis or after a GFD (Table   3A) . Even when data were analyzed according to the presence or absence of iron deficiency anemia, the distribution of the H63D genotype differed among the non-IDA celiac patients at diagnosis and follow-up while no differences were observed in IDA subjects for HFE (C282Y) mutation (Table 3B ). In IDA and non-IDA celiac patients, the presence of one or the other TMPRSS6 genotypes did not influence iron parameters at diagnosis, but a difference in Hb, serum iron and ferritin levels were observed after a GFD in IDA subjects (P < .001) (Table   3B ). In particular, these differences were observed in patients with persistent IDA despite their clinical responsiveness to GFD (45.4% of IDA patients). Considering patients underwent an iron supplementation program (76% of IDA patients), differences in hemoglobin or iron parameters were shown in this group compared with no treated IDA patients IDA, iron deficiency anaemia; GFD, gluten free diet; Hb, haemoglobin; MCV: mean corpuscular volume; n, number; SD, standard deviation. Nucleotide change is reported in parentheses ().
FIG URE 1
Hematological and iron parameters according to TMPRSS6 genotype and to iron supplementation in IDA persistent and IDA not persistent CD patients. Hemoglobin (Hb), serum iron, and ferritin levels in IDA persistent and in IDA not persistent patients both at diagnosis (D) and at follow-up (F) according to different TMPRSS6 genotypes (CC, CT, or TT). IDA persistent (filled bars, N 5 83) and IDA not persistent (empty bars, N 5 91) were both on gluten-free diet and iron supplementation at follow-up. The data are presented as means 6SD; statistically significant differences were determined by Student's t-test, *P < .05, **P < .001, ***P < .0001. The graphs were created using the Software GraphPad Prism 6 according to genotypes (Figure 1 and Supporting Information, Table   3S ).
| Hepcidin analysis
Hepcidin was measured at diagnosis (53 CD patients) and at follow-up after a GDF (200 CD patients). Hematological and iron parameters of these subgroups of patients were reported in Supporting Information, Tables 4S and 5S . Decreased serum hepcidin values were observed more in the anemic patients than those observed in nonanemic subjects at diagnosis (2.63 6 4.60 vs 3.31 6 4.56, P 5 .6) (Supporting Information, Table 5S ) and at follow-up (1.22 6 1.14 vs 2.08 6 2.15, Table   1S ), the major effect of variant (rs855791) V736A on hepcidin production.
Next, we correlated the hepcidin values, after GFD, with the genotype to verify a possible effect of TMPRSS6 rs855791 variant on hematological and iron parameters. In IDA CD patients, serum hepcidin levels were lower in AA (C, WT allele) compared with VV (T, risk allele)
homozygous individuals (1.1 6 0.9 vs 1.6 6 1.7) (Supporting Information, Table 4S ). This difference was evident both in IDA persistent and in IDA non-persistent CD subjects, although not significant (P 5 .30
and .57, respectively) (Supporting Information, Table 4S ).
| D I SCUSSION
Iron-deficiency anemia (IDA) is often the presenting complaint in adults diagnosed with CD, with estimated prevalence ranging from 12% to 69%. 24, 25 The results of our study confirm the high prevalence of anemia in untreated celiac disease (45.3%). Although GFD is an effective treatment for CD, IDA remains an occasional finding during follow-up and correlates to inadequate gluten exclusion. 24 Unfortunately, the relationship between IDA and CD has been poorly investigated. In this study, we investigated the role of HFE and TMPRSS6 variants in IDA, both at diagnosis and follow-up. As IDA is common in patients with CD as a consequence of iron malabsorption resulting from villous atrophy, we examined the effect of the severity of villous damage at diagnosis on hematologic parameters. We found that the proportion of anemic and nonanemic individuals did not differ by degree of villous atrophy (85.9% Marsh grade 3 in the nonanemic group versus 83% in the anemic group of patients, P 5 .6). Previously, controversial results were obtained about a possible protective role of HFE mutation against the development of IDA in CD patients. Butterworth et al. 26 showed that CD patients with the C282Y mutation had higher fasting serum iron and hemoglobin levels at the time of CD diagnosis than those with wild-type HFE genotype. By contrast, two Italian studies demonstrated that HFE mutations did not constitute a protective factor against the development of anemia in patients with untreated CD. 27, 28 In our study, CD patients had a significantly higher frequency of C282Y mutation compared to healthy controls, but the allelic frequency of C282Y was significantly higher in IDA versus non-IDA celiac patients, countering the concept that this mutation offers protection from IDA. In addition, both at the diagnosis and after GFD, celiac patients with the C282Y mutation did not have higher hemoglobin or serum iron levels compared to those with wild-type genotype (Table 3A,B) . We did not find statistically significant differences in the prevalence of H63D mutation between celiac patients and controls (Table 1) . Moreover, both at diagnosis and after a GFD, the celiac patients with H63D mutation, that is, non-IDA subjects, showed higher hemoglobin and serum iron than those with the wild-type HFE genotype. Large-scale population studies have revealed that most HFE mutation carriers with a mild iron overload-phenotype lack any clinically relevant disease symptoms, leading to the hypothesis that HFE mutations may confer a genetic advantage on asymptomatic hemochromatosis "patients" and have, therefore, continued to spread. 29 The C282Y variant is considered to play the most important role in iron metabolism. However, in our study, we were not able to directly confirm this result. For this reason, we speculate that certain HFE gene mutations could provide a survival advantage by ameliorating the iron deficiency seen in celiac patients, although controversial results have been achieved, including our work in which the beneficial impact of the H63D variant on hemoglobinization and iron parameters is not consistent with the C282Y variant.
Clearly, our results were limited because of a small number of H63D homozygote patients, whereas we found no C282Y homozygote or C282Y/H63D heterozygote compound patients. It is possible to speculate that hemoglobin and ferritin amelioration could be expected in case of C282Y homozygosity or C282Y/H63D compound heterozygosity, in accordance with Butterworth et al. 26 It has been hypothesized that a linkage between C282Y mutation and HLA loci, especially DQ2, could explain the protective effect of HFE in CD. In effect, when investigating the role of HLA loci in accordance with HFE mutations, we found no statistically significant differences between IDA and non-IDA CD subjects after the abovementioned adjustment (Supporting Information, Table 2S ). These results were in contrast with those found by Butterworth et al., who observed that HFE gene mutations were common and were in linkage disequilibrium with different HLA alleles in CD patients. However, without controlling for the differences in the distribution of HLA DR-DQ haplotypes among patients and controls, their reported association may well only be secondary to linkage disequilibrium with the disease-associated DR3-DQ2
haplotype. 30 Probably, as there is a gradient of both HFE mutations and HLA patterns across Europe, the observed HLA association differences between Butterworth's results and our results may simply be reflecting ethnogeographic differences. 31 In accordance with our results, the role of HFE mutations has been explored in the contest of chronic hemodialysis patients, where mutations might confer an adaptive benefit by decreasing hepcidin release, thus improving iron availability to erythropoiesis, anemia control, and the response to erythropoiesis-stimulating agents and iron itself. 32 It has been reported that TMPRSS6 polymorphisms may have a role in increasing the risk of IDA. 33 The SNP rs855791, which causes the MT2 V736A amino acid substitution, is the most associated polymorphism with iron and hematologic parameters, consistent with the hypothesis that this variant influences hepcidin-regulated iron homeostasis. 11, 34 We investigated the prevalence of such TMPRSS6 rs855791
in a large series of CD patients (505) both at diagnosis and after GFD (one year of treatment). We found that the V736A variant was not different from healthy controls (Table 1) .
Furthermore, we evaluated TMPRSS6 variant in IDA versus non-IDA celiac subjects and the influence of this on hematologic parameters (Tables 2 and 3B Hb, serum iron, and ferritin levels. For the first time, Elli et al. 35 recently evaluated the role of TMPRSS6 in CD patients with IDA persistence against non-IDA CD and non-CD subjects. The authors found a significantly higher percentage of TMPRSS6 mutation in 33 CD patients than in non-CD controls, while no differences were found between IDA and non-IDA CD patients. Conversely, in our study involving a vaster population, we did not find any significant difference in terms of TMPRSS6 genotype or allelic frequencies between CD patients and healthy controls, but a statistically significant difference was found between IDA and non-IDA CD patients ( Table 2) .
Because of a role of TMPRSS6 variant in the refractoriness to oral iron, 36 we also consider IDA CD patients after oral iron supplementation, both on GFD. Even presenting comparable clinical parameters (Hb, serum iron, and ferritin levels) at diagnosis, TMPRSS6 variant seems to play a role only in 83 IDA-persistent treated subjects (47.7% of totally IDA treated) considering the lower hematological and iron parameters response to oral iron according to genotype after one year ( Figure 1 and Supporting Information, Table 3S ). Furthermore, after a follow-up period, our study revealed that in 91 (52.3%) IDA CD patients treated with oral iron, anemia did not persist and no genotype-phenotype correlation was present (Supporting Information, Table 3S ). Overall, these results confirm that TMPRSS6 genotype is important in predicting oral iron response in IDA subjects. At the same time, the discrepancy between the TMPRSS6 mutations and their phenotypic expression in IDA nonpersistent treated patients indicates that additional environmental or genetic factors contribute to the manifestation of IDA in affected individuals (IDA-persistent). A proof of concept of this speculation is that among IDA not subjected to iron treatment, IDA-non-persistent subjects improve anemia compared to IDA-persistent subjects (Supporting Information, Table 3S ). Coherently to the decreased iron parameters, serum hepcidin levels were lower in iron-deficient subjects compared to non-IDA, both at diagnosis and follow-up, reflecting an appropriate physiologic response to decreased circulating levels of iron. 37 These results were in accordance with those found by Elli et al. 35 This pathological situation probably reflects the eventual effect of variant rs855791 on hepcidin production 16 as IDApersistent subjects showed higher allelic frequency of V736 TMPRSS6
variant. In order to address this question, we correlated hepcidin values with the genotype to verify a possible effect of MT2 variant, after a GDF. Hepcidin was higher in IDA patients carrying T allele (V736) compared to wild-type subjects (Supporting Information, Table 4S ), most pronounced in IDA-persistent subjects than in IDA-non-persistent subjects. Given that inflammatory cytokines influence iron metabolism through hepcidin stimulation, 38 we consider a possible role of mucosa inflammation in increasing hepcidin (and ferritin) levels. The role of hepcidin in inflammatory anemia is well-known in inflammatory bowel disease as well. 39 In IDA non-persistent subjects, the high hepcidin levels in TT subjects is probably due to an inflammatory state (Supporting Information, Table 3S ), whereas in IDA-persistent TMPRSS6 allele risk (T allele) should have a predominant role in increasing hepcidin levels ( Figure 1 and Supporting Information, Table 3S ). In accordance with Zanella et al., 40 the hypothesis that the increased hepcidin (and ferritin) levels in some of the nonanemic patients has been due to mild inflammatory status appears reasonable and could be investigated using matching genotypic and bioptic data to prove eventual effects of TMPRSS6 variant and Marsh's classification of the mucosa of the duodenum, although we did not find any statistically significant difference in terms of villous atrophy at the time of CD diagnosis between anemic and nonanemic CD patients (Table 2) . Moreover, the number of TT subjects was higher in the IDA-persistent subgroup with respect to IDA-non-persistent subgroup. This provides further evidence that TMPRSS6 indirectly modifies hematological and iron traits through its direct effects on hepcidin.
In accordance with our findings, Pelusi et al. 41 demonstrated that TMPRSS6 genotype influenced hepcidin levels, erythropoiesis, and anemia management also in chronic hemodialysis patients, concluding that the evaluation of the effect of TMPRSS6 genotype on clinical outcomes in prospective studies in hemodialysis may be useful to predict the outcomes of hepcidin manipulation and to guide treatment personalization by optimizing anemia management.
Starting from these assumptions, the evaluation of TMPRSS6 genotype in anemic CD patients at the time of CD diagnosis could be of clinical relevance, thus guiding the clinician in the iron supplementation therapeutic management (oral vs parenteral iron administration), whereas CD subjects with mutation seemed not to respond to oral iron therapy.
Our work has some limitations that we now briefly discuss: firstly, iron treatment was not standardized throughout the study. However, it was a case-by-case decision on the basis of clinical benefit from iron treatment for each patient. Secondly, our CD population consisted of 79% females, in accordance with the epidemiology of CD, while females were only 41% in the control group. It is clear that women of childbearing age have a higher propensity to be anemic. However, when we made a subanalysis only on males, we found the same results.
Moreover, among IDA patients treated with intravenous iron, we found 3 subjects with persistent IDA and 4 patients without persistent IDA.
No differences in TMPRSS6 variant allelic frequency were found among these patients, confirming the involvement of genetic factors as well as other environmental actors in IDA onset in CD patients. Further studies are needed to clarify the effects of TMPRSS6 variant in CD patients treated with intravenous iron. Oral iron treatment is relatively inexpensive and safe, but we believe that it could be better to know if an IDA patient has a genetic mutation involved in the oral iron response at the time of CD diagnosis.
In conclusion, our study confirms the role of TMPRSS6 in predicting oral iron response modulating hepcidin action on iron absorption.
Moreover, we showed that the management of oral iron therapy in selected CD patients could depend on TMPRSS6 genotype that could predict persistent IDA despite oral iron supplementation and a GFD. At The manuscript-including related data, figures, and tables-has not been previously published and the manuscript is not under consideration elsewhere. This work is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried. If accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright holder.
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